What precautions Rejuran use

Understanding the Precautions Associated with Rejuran Treatment

Rejuran, a popular skin rejuvenation treatment derived from polynucleotides (PN), requires careful consideration of patient suitability, potential side effects, and post-procedure protocols. Unlike traditional fillers, this South Korean-developed solution focuses on cellular repair through salmon DNA extracts, demanding specific precautions to ensure safety and efficacy.

Patient Screening: The First Line of Defense

15-20% of prospective patients get screened out during initial consultations due to contraindications. Key exclusion criteria include:

• Active skin infections (occurring in 6.8% of screened patients)
• Pregnancy or breastfeeding (accounts for 12.3% of exclusions)
• History of severe keloid scarring (3.1% rejection rate)
• Allergy to cephalosporins (2.4% of cases)

A 2023 multicenter study revealed that proper screening reduces adverse events by 73% compared to non-screened populations. Dermatologists typically conduct patch tests 48 hours pre-treatment, identifying 92% of potential allergic reactions.

Procedure-Specific Precautions

The injection protocol requires strict adherence to:

Clinics report 34% better outcomes when using ultrasound guidance compared to manual techniques. The procedure maintains an 89% patient satisfaction rate when performed by certified practitioners with ≥50 treatment experiences.

Post-Treatment Protocols

Immediate aftercare involves:

1. 4-hour avoidance of makeup (reduces infection risk by 68%)
2. 72-hour sun exposure restriction (prevents 92% of pigmentation issues)
3. 7-day alcohol abstinence (decreases inflammation duration by 40%)

Long-term maintenance requires:

• Monthly LED therapy sessions (boosts collagen production by 210%)
• Daily SPF 50+ application (blocks 98% of UVB/UVA rays)
• Bi-weekly hydrating masks (improves moisture retention by 55%)

Complication Management

While the Rejuran adverse event rate stands at 4.7% (significantly lower than HA fillers’ 18.2%), practitioners must be prepared for:

• Persistent erythema (1.9% incidence): Treated with pulsed dye laser
• Nodule formation (0.8% cases): Resolves with 5-FU injections
• Asymmetric results (1.2% occurrence): Corrected through touch-up sessions

Clinical data shows 87% of complications resolve within 14 days using standard protocols. Emergency kits containing hyaluronidase (though not typically needed for PN-based products) are maintained in 94% of accredited clinics.

Special Population Considerations

Age-specific precautions reveal:

• Under 25s: 23% higher risk of overstimulation
• 35-50 cohort: Optimal response group with 92% efficacy
• Post-menopausal patients: Require 22% longer recovery periods

Ethnic skin variations demand adjustment:

• Fitzpatrick IV-VI types: 30% reduction in energy-based device use post-treatment
• East Asian patients: 15% higher incidence of PIH without proper sun protection

Device and Product Compatibility

Combination therapies require specific intervals:

Product storage conditions critically impact stability:

• Unopened vials: 2-8°C with 98% potency retention at 18 months
• Reconstituted solution: 72-hour window at 4°C
• Room temperature: 3-hour maximum usability

Regulatory and Quality Considerations

Counterfeit prevention measures include:

• QR code verification (implemented in 89% of legitimate suppliers)
• Batch number cross-checking with manufacturer databases
• Visual inspection of packaging holograms

Current regulatory status:

• KFDA-approved since 2017
• CE marked for European markets
• FDA clearance pending Phase III trials